<DOC>
	<DOCNO>NCT01108666</DOCNO>
	<brief_summary>Seventy two patient ask take part research study diagnose Stage IIIA IIIB non-small cell lung cancer ( NSCLC ) . This study do determine high safe dose proton beam radiotherapy and/or study drug ( call Nelfinavir ) give concurrent chemoradiotherapy patient cancer without cause bad side effect ; develop biomarker clinical outcome . This study do two phase . In first phase , feasibility establish . We follow patient treatment course record side effect standard proton radiation dose give together Cisplatinum + Etoposide Carboplatin + Paclitaxel . In second phase , see possible increase total proton radiation dose study drug without increase number bad side effect treat together chemotherapy drug .</brief_summary>
	<brief_title>Proton Beam Radiation With Concurrent Chemotherapy Nelfinavir Inoperable Stage III Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Overall objective : 1 . Determine MTD proton beam radiotherapy concurrent cisplatin etoposide stage III NSCLC . 2 . Determine MTD proton beam radiotherapy concurrent carboplatin paclitaxel stage III NSCLC non-cisplatin candidate . 3 . Determine MTD Nelfinavir concurrent chemoradiotherapy stage III NSCLC RPTD proton beam radiotherapy . 4 . Develop biomarker clinical outcome concurrent chemoradiotherapy stage III NSCLC . 5 . To determine clinical efficacy , define metabolic response , sit recurrence ( e.g. , local , regional , distant ) progression-free overall survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>1 . Histologically confirm diagnosis NSCLC . 2 . Stage IIIA IIIB NSCLC . 3 . Patients must evidence metastatic disease base routine imaging . 4 . Patients must Karnofsky Performance Status 60 . 5 . Age 18 old . 6 . Patients must able provide inform consent . 7 . Adequate bone marrow function ( i.e . WBC large equal 4000/mm3 , platelet large equal 100,000 mm3 ) . 8 . Adequate renal function cisplatin carboplatin determine medical oncologist : Usually Calculated creatinine clearance ( CrCl ) large equal 45 mL/min serum creatinine level small equal to1.5 x institutional ULN . 9 . Patients must bilirubin 1.5 mg/dl . 10 . Women childbearing potential long agree use recognize method birth control ( e.g . oral contraceptive , IUD , condom barrier method etc ) . 11 . Hysterectomy menopause must clinically document . 1 . Prior simultaneous malignancy within past two year ( cutaneous squamous basal cell carcinoma melanoma situ ) . 2 . Pregnant woman , woman plan become pregnant woman nurse . 3 . Actively treat research study . 4 . For Nelfinavir phase trial : Patients take Antiarrhythmics ( amiodarone , quinidine ) , Antimycobacterial ( rifampin ) , Ergot Derivatives ( dihydroergotamine , ergonovine , ergotamine , ethylergonovine ) , Herbal Products ( St. John 's wort/ hypericum perforatum ) , HMGCoA Reductase Inhibitors ( lovastatin , simvastatin ) , Neuroleptic ( pimozide ) , Proton Pump Inhibitors , Sedative/ Hypnotics ( midazolam , triazolam ) . Note : Patients follow condition deem unsuitable cisplatinbased chemotherapy ( treated carboplatin ) : ( ) Hearing impairment/ peripheral neuropathy Grade 1 less baseline ( b ) Symptomatic/uncontrolled congestive heart failure ( unable tolerate volume load pre postcisplatin hydration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adult subject confirm diagnosis Stage IIIA IIIB NSCLC , adequate bone marrow , liver renal function .</keyword>
</DOC>